Intervention Review

You have free access to this content

Postpartum misoprostol for preventing maternal mortality and morbidity

  1. G Justus Hofmeyr1,*,
  2. A Metin Gülmezoglu2,
  3. Natalia Novikova3,
  4. Theresa A Lawrie4

Editorial Group: Cochrane Pregnancy and Childbirth Group

Published Online: 15 JUL 2013

Assessed as up-to-date: 2 APR 2013

DOI: 10.1002/14651858.CD008982.pub2


How to Cite

Hofmeyr GJ, Gülmezoglu AM, Novikova N, Lawrie TA. Postpartum misoprostol for preventing maternal mortality and morbidity. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD008982. DOI: 10.1002/14651858.CD008982.pub2.

Author Information

  1. 1

    University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health, Department of Obstetrics and Gynaecology, East London Hospital Complex, East London, Eastern Cape, South Africa

  2. 2

    World Health Organization, UNDP/UNFPA/WHO/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Department of Reproductive Health and Research, Geneva, Switzerland

  3. 3

    Walter Sisulu University, Department of Obstetrics and Gynaecology, East London Hospital Complex, East London, South Africa

  4. 4

    Royal United Hospital, The Cochrane Gynaecological Cancer Group, Bath, UK

*G Justus Hofmeyr, Department of Obstetrics and Gynaecology, East London Hospital Complex, University of the Witwatersrand, University of Fort Hare, Eastern Cape Department of Health, Frere and Cecilia Makiwane Hospitals, Private Bag X 9047, East London, Eastern Cape, 5200, South Africa. justhof@gmail.com.

Publication History

  1. Publication Status: New
  2. Published Online: 15 JUL 2013

SEARCH

[Figure 1]
Figure 1. 'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.
[Figure 2]
Figure 2. Funnel plot of comparison: 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, outcome: 1.1 Maternal deaths.
[Figure 3]
Figure 3. Funnel plot of comparison: 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, outcome: 1.2 Maternal deaths or severe morbidity.
[Figure 4]
Figure 4. Funnel plot of comparison: 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, outcome: 1.4 Maternal deaths or severe morbidity excluding hyperpyrexia.
[Figure 5]
Figure 5. Funnel plot of comparison: 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, outcome: 1.5 Pyrexia ≥ 38°C.
[Analysis 1.1]
Analysis 1.1. Comparison 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, Outcome 1 Maternal deaths.
[Analysis 1.2]
Analysis 1.2. Comparison 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, Outcome 2 Maternal deaths or severe morbidity.
[Analysis 1.3]
Analysis 1.3. Comparison 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, Outcome 3 Maternal deaths or severe morbidity (sensitivity analysis).
[Analysis 1.4]
Analysis 1.4. Comparison 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, Outcome 4 Maternal deaths or severe morbidity excluding hyperpyrexia.
[Analysis 1.5]
Analysis 1.5. Comparison 1 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator, Outcome 5 Pyrexia ≥ 38°C.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator and indication, Outcome 1 Maternal deaths.
[Analysis 2.2]
Analysis 2.2. Comparison 2 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator and indication, Outcome 2 Maternal deaths or severe morbidity.
[Analysis 2.3]
Analysis 2.3. Comparison 2 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator and indication, Outcome 3 Maternal deaths or severe morbidity excluding hyperpyrexia.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Misoprostol versus control (placebo or uterotonic) subgrouped by comparator and indication, Outcome 4 Pyrexia ≥ 38°C.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Misoprostol vs control subgrouped by misoprostol dose, Outcome 1 Maternal deaths.
[Analysis 3.2]
Analysis 3.2. Comparison 3 Misoprostol vs control subgrouped by misoprostol dose, Outcome 2 Maternal deaths or severe morbidity.
[Analysis 3.3]
Analysis 3.3. Comparison 3 Misoprostol vs control subgrouped by misoprostol dose, Outcome 3 Maternal deaths or severe morbidity (sensitivity analysis).
[Analysis 3.4]
Analysis 3.4. Comparison 3 Misoprostol vs control subgrouped by misoprostol dose, Outcome 4 Maternal deaths or severe morbidity excluding hyperpyrexia.
[Analysis 3.5]
Analysis 3.5. Comparison 3 Misoprostol vs control subgrouped by misoprostol dose, Outcome 5 Pyrexia ≥ 38°C.
[Analysis 4.1]
Analysis 4.1. Comparison 4 Misoprostol vs control subgrouped by route of administration, Outcome 1 Maternal deaths.
[Analysis 4.2]
Analysis 4.2. Comparison 4 Misoprostol vs control subgrouped by route of administration, Outcome 2 Maternal deaths or severe morbidity.
[Analysis 4.3]
Analysis 4.3. Comparison 4 Misoprostol vs control subgrouped by route of administration, Outcome 3 Maternal deaths or severe morbidity excluding hyperpyrexia.